Two Japan deep-tech startups complete Series B second closes
Helical Fusion and Celaid Therapeutics have raised JPY3.23bn and JPY400m, respectively, as Japanese capital targets research-intensive startups.
October 09, 2026
An ageing population in Asia has expanded the scope for pharmaceutical companies. And countries, in turn, are using regulation to speed up the drug development process as they embrace a dynamic life science market.
Registered users get 2 free articles in 30 days.
Subscribers have full unlimited access to FinanceAsia.
Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.
Questions?
See here for more information on licences and prices, or contact [email protected].